- Home
- CTSO vs INCR Comparison
CTSO vs INCR Comparison
Compare CTSO & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- INCR
- Stock Information
- Founded
- CTSO 1997
- INCR 1994
- Country
- CTSO United States
- INCR Israel
- Employees
- CTSO N/A
- INCR N/A
- Industry
- CTSO Medical/Dental Instruments
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- INCR Health Care
- Exchange
- CTSO Nasdaq
- INCR Nasdaq
- Market Cap
- CTSO 73.5M
- INCR 84.7M
- IPO Year
- CTSO N/A
- INCR N/A
- Fundamental
- Price
- CTSO $1.19
- INCR $1.87
- Analyst Decision
- CTSO Strong Buy
- INCR
- Analyst Count
- CTSO 3
- INCR 0
- Target Price
- CTSO $4.67
- INCR N/A
- AVG Volume (30 Days)
- CTSO 118.0K
- INCR 23.9K
- Earning Date
- CTSO 11-07-2024
- INCR 10-29-2024
- Dividend Yield
- CTSO N/A
- INCR N/A
- EPS Growth
- CTSO N/A
- INCR N/A
- EPS
- CTSO N/A
- INCR N/A
- Revenue
- CTSO $37,159,990.00
- INCR $72,420,918.00
- Revenue This Year
- CTSO $11.14
- INCR N/A
- Revenue Next Year
- CTSO $17.07
- INCR $52.65
- P/E Ratio
- CTSO N/A
- INCR N/A
- Revenue Growth
- CTSO 2.17
- INCR N/A
- 52 Week Low
- CTSO $0.70
- INCR $0.99
- 52 Week High
- CTSO $2.15
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- CTSO 45.86
- INCR 45.85
- Support Level
- CTSO $1.26
- INCR $1.81
- Resistance Level
- CTSO $1.59
- INCR $1.89
- Average True Range (ATR)
- CTSO 0.16
- INCR 0.08
- MACD
- CTSO -0.03
- INCR 0.01
- Stochastic Oscillator
- CTSO 14.89
- INCR 44.00
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.